Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05898594 · ClinicalTrials.gov registry record · NA
Lung Cancer Screening in High-risk Black Individuals
A NA study of Lung Cancer and Lung Carcinoma, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 900
- Enrollment target
- 2
- Study locations
NCT05898594: Recruiting NA study of Lung Cancer and Lung Carcinoma, sponsored by Massachusetts General Hospital.
NCT05898594 is a NA study of Lung Cancer and Lung Carcinoma that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 900 participants, roughly in line with the 934-participant average among 409 other Lung Cancer trials with a reported enrollment target. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05898594, a NA study of Lung Cancer and Lung Carcinoma, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 900 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this research study is to study U.S. Black individuals with a history of smoking to examine the feasibility, acceptability, and performance of low-dose computed tomography (LDCT) screening among this population. The name of the intervention used in this research study is: Low-dose computed tomography (radiologic scan) chest scan
Primary Outcome
Primary endpoint is feasibility. Feasibility is defined as the percentage of individuals invited to participate in the trial who enroll.
Conditions Studied
Interventions
- PROCEDURE Low-dose Computed Tomography
Study Locations (2)
Illinois
- University of Chicago - Chicago
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2023-09-06 |
| Est. Completion | 2028-06-30 |
| Phase | NA |
What NCT05898594 shows while recruiting
NCT05898594 is an interventional study that assigns participants to a tested intervention. The registered 900 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 934-participant average among 409 other Lung Cancer trials with a reported enrollment target.
The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Low-dose Computed Tomography is the first listed.
NCT05898594 reports a single indexed study location in Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05898594 about?
NCT05898594 is a clinical study titled "Lung Cancer Screening in High-risk Black Individuals". The goal of this research study is to study U.S. Black individuals with a history of smoking to examine the feasibility, acceptability, and performance of low-dose computed tomography (LDCT) screening among this population. The name of the intervention used in this research study is: Low-dose comp...
What is the current status of trial NCT05898594?
This trial is currently recruiting. It is a NA study. The enrollment target is 900 participants. The study started on 2023-09-06. Estimated completion is 2028-06-30.
What conditions does trial NCT05898594 study?
This clinical trial studies the following conditions: Lung Cancer, Lung Carcinoma.
What interventions are being tested in trial NCT05898594?
The interventions under investigation include: Low-dose Computed Tomography (PROCEDURE).
Who is sponsoring clinical trial NCT05898594?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05898594 being conducted?
This trial has 2 study locations across Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05898594's enrollment target sits among peer trials
900 52nd of 409 higher than 358 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
-
A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
RECRUITING · NA
-
Exercise as Maintenance Therapy in Advanced Lung Cancer
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Stereotactic Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Virtual Agent Feasibility in Oncology Patients (NTT Data)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
- NCT02960022 · 900 participants · Phase 2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI